IP Library Granted Patent US 9,328,119
Granted Patent B2
US 9,328,119 · App. 14/482,886 · Granted May 3, 2016

AZA-pyridone compounds and uses thereof

Inventors: Robert Than Hendricks (San Carlos, CA); Leonid Beigelman (San Mateo, CA); David Bernard Smith (San Mateo, CA); Antitsa Dimitrova Stoycheva (Half Moon Bay, CA)
Assignee: Alios BioPharma, Inc.
C07D487/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,328,119
App. No.
14/482,886
Granted
May 3, 2016
Kind
B2
Abstract

Disclosed herein are aza-pyridone compounds, pharmaceutical compositions that include one or more aza-pyridone compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an orthomyxovirus infection, with an aza-pyridone compounds. Examples of an orthomyxovirus viral infection include an influenza infection.

Claims (71)

1. A compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the compound of Formula (I) has the structure:

wherein:

is a single bond or double bond;

R 1 is selected from the group consisting of hydrogen, an unsubstituted C 1-4 alkyl, —C(═O)Y 1 , —C(═O)—O—Y 1 , —(CH 2 )—O—(C═O)—Y 1 , —(CH 2 )—O—(C═O)—O—Y 1 , —(CHCH 3 )—O—(C═O)—Y 1 and —(CHCH 3 )—O—(C═O)—O—Y 1 ;

R 2 is selected from the group consisting of hydrogen, an optionally substituted C 1-6 alkyl, an optionally substituted heterocyclyl, an optionally substituted cycloalkyl(C 1-6 alkyl), an optionally substituted aryl(C 1-6 alkyl), an optionally substituted heteroaryl(C 1-6 alkyl) and an optionally substituted heterocyclyl(C 1-6 alkyl);

R 3a and R 3b are independently hydrogen or an optionally substituted C 1-4 alkyl;

R 4 and R 5 are independently selected from the group consisting of hydrogen, an optionally substituted aryl, an optionally substituted aryl(C 1-6 alkyl) an optionally substituted heteroaryl and an optionally substituted heteroaryl(C 1-6 alkyl), provided that at least one of R 4 and R 5 is not hydrogen; or

R 4 and R 5 are taken together to form an optionally substituted tricyclic cycloalkenyl or an optionally substituted tricyclic heterocyclyl;

R 6 is selected from the group consisting of hydrogen, halogen, —CN, an optionally substituted C 1-6 alkyl, an optionally substituted aryl, an optionally substituted heteroaryl, —CH 2 OH, —CH(Y 2 )(OH) and —C(O)Y 2 ;

Y 1 and Y 2 are independently selected from the group consisting of an optionally substituted C 1-6 alkyl, an optionally substituted C 3-6 cycloalkyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted heterocyclyl, a mono-substituted amino group, a di-substituted amino and —C(R 7 )NHR 8 ; and

R 7 and R 8 are independently hydrogen or an optionally substituted C 1-4 alkyl.

2. The compound of claim 1 , wherein R 4 is an optionally substituted aryl.

3. The compound of claim 2 , wherein the optionally substituted aryl is an optionally substituted phenyl.

4. The compound of claim 1 , wherein R 4 is an optionally substituted heteroaryl.

5. The compound of claim 1 , wherein R 5 is an optionally substituted aryl.

6. The compound of claim 5 , wherein the optionally substituted aryl is an optionally substituted phenyl.

7. The compound of claim 1 , wherein R 5 is an optionally substituted heteroaryl.

8. The compound of claim 1 , wherein R 4 and R 5 are taken together to form an optionally substituted tricyclic heterocyclyl.

9. The compound of claim 8 , wherein the optionally substituted tricyclic heterocyclyl is an optionally substituted moiety selected from the group consisting of:

10. The compound of claim 1 , wherein R 2 is hydrogen.

11. The compound of claim 1 , wherein R 2 is an optionally substituted C 1-6 alkyl.

12. The compound of claim 11 , wherein R 2 is an unsubstituted C 1-6 alkyl.

13. The compound of claim 1 , wherein R 2 is an optionally substituted aryl(C 1-6 alkyl).

14. The compound of claim 1 , wherein R 1 is hydrogen.

15. The compound of claim 1 , wherein R 1 is an unsubstituted C 1-4 alkyl.

16. The compound of claim 1 , wherein R 1 is —C(═O)Y 1 , —C(═O)—O—Y 1 , —(CH 2 )—O—(C═O)—Y 1 , —(CH 2 )—O—(C═O)—O—Y 1 , —(CHCH 3 )—O—(C═O)—Y 1 or —(CHCH 3 )—O—(C═O)—O—Y 1 .

17. The compound of claim 16 , R 1 is —C(═O)Y 1 .

18. The compound of claim 16 , R 1 is —C(═O)—O—Y 1 .

19. The compound of claim 1 , wherein R 6 is hydrogen.

20. The compound of claim 1 , wherein R 3a is hydrogen; and R 3b is hydrogen.

21. The compound of claim 1 , wherein is a single bond.

22. The compound of claim 1 , wherein is a double bond.

23. The compound of claim 1 , wherein the compound is selected from the group consisting of:

or a pharmaceutically acceptable salt of the foregoing.

24. The compound of claim 1 , wherein the compound is selected from the group consisting of:

or a pharmaceutically acceptable salt of the foregoing.

25. The compound of claim 1 , wherein the compound is selected from the group consisting of:

or a pharmaceutically acceptable salt of the foregoing.

26. A pharmaceutical composition comprising an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, excipient, or combination thereof.

27. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

28. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

29. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

30. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

31. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

32. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

33. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

34. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

35. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

36. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

37. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

38. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

39. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

40. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

41. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

42. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 10, 2023
From: JANSSEN PHARMACEUTICA NV
To: JANSSEN PHARMACEUTICALS, INC.
Reel/Frame 063601/0912 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 12, 2022
From: JANSSEN BIOPHARMA, LLC
To: JANSSEN PHARMACEUTICA NV
Reel/Frame 059681/0844 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 19, 2014
From: HENDRICKS, ROBERT THAN; BEIGELMAN, LEONID; SMITH, DAVID BERNARD; STOYCHEVA, ANTITSA DIMITROVA
To: ALIOS BIOPHARMA, INC.
Reel/Frame 033776/0173 →
Continuity (4)
Provisional Application 62031673 · Jul 31, 2014
Provisional Application 62011784 · Jun 13, 2014
Provisional Application 61877151 · Sep 12, 2013
Related Publication 20150072982A1 · Mar 12, 2015